http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0708483-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47e6d64f3ca7f88ca5541672f0e21dca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate | 2007-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2493cbefa0cd666ac05a82395c5d533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd526698185cd48eccdf815ce4ac5e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e40f0caf7cd39932eb5bf1d87ffea84 |
| publicationDate | 2011-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0708483-A2 |
| titleOfInvention | latrunculin pharmaceutical formulations |
| abstract | PHARMACEUTICAL FORMULATIONS OF LATRUNCULIN The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% by weight / volume, a non-ionic surfactant in an amount of 0.01- 2% by weight / volume , and a tonicity agent to maintain a tonicity between 200-400 mOsmlkG, at a pH between 4 to 8, where latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six months at refrigerated temperature. The present invention also provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis. |
| priorityDate | 2006-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.